CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...